T1	p 70 125	due to house dust mite Dermatophagoides pteronyssinus :
T2	p 168 181	immunotherapy
T3	p 295 318	house dust mite ( HDM )
T4	p 387 421	10 patients with asthma due to HDM
T5	p 427 434	studied
T6	p 467 468	(
T7	p 533 545	5 patients (
T8	p 882 897	2 patients lost
T9	p 969 970	.
T10	p 1427 1440	asthma due to
T11	i 6 25	Local immunotherapy
T12	i 29 39	inhalation
T13	i 43 59	a powder extract
T14	i 83 125	dust mite Dermatophagoides pteronyssinus :
T15	i 157 183	parenteral immunotherapy .
T16	i 231 257	local immunotherapy ( LI )
T17	i 261 271	inhalation
T18	i 275 310	a powder extract of house dust mite
T19	i 340 371	parenteral immunotherapy ( PI )
T20	i 477 478	)
T21	i 489 530	LI and subcutaneous injections of placebo
T22	i 552 553	B
T23	i 566 568	PI
T24	i 587 594	lactose
T25	i 657 697	premedication with disodium cromoglycate
T26	i 717 718	.
T27	i 1037 1049	methacholine
T28	i 1069 1103	nebulized distilled water ( UNDW )
T29	o 198 210	efficacy and
T30	o 215 227	tolerability
T31	o 753 826	in symptoms score and in peak expiratory flow ( PEF ) -derived parameters
T32	o 902 916	late component
T33	o 924 942	bronchial response
T34	o 1019 1033	responsiveness
T35	o 1111 1154	immunologic humoral and cellular parameters
T36	o 1158 1174	peripheral blood
T37	o 1212 1245	local important adverse reactions
T38	o 1278 1299	systemic side effects
T39	o 1572 1593	systemic side effects